Molecular Targeted Therapies in Metastatic Prostate Cancer: Recent Advances and Future Challenges
Cancers · 23.05.2023 · 15 (11) · 2885
DOI: 10.3390/cancers15112885 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 23.05.2023. Verfasst von Carlo Sorrentino und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Sciences of Aging, "G. d'Annunzio" University of Chieti-Pescara, 66100 Chieti, Italy. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 123 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Association for Cancer Research, Ministero dell'Università e della Ricerca, AIRC (Associazione Italiana per la Ricerca sul Cancro).
Abstract (Originalsprache)
Prostate cancer is the most frequent malignant tumor in men, and, despite the great improvements in survival in patients with localized cancer, the prognosis for metastatic disease remains poor. Novel molecular targeted therapies, which block specific molecules or signaling pathways in tumor cells or in their microenvironment, have shown encouraging results in metastatic castration-resistant prostate cancer. Among these therapeutic approaches, prostate-specific membrane antigen-targeted radionuclide therapies and DNA repair inhibitors represent the most promising ones, with some therapeutic protocols already approved by the FDA, whereas therapies targeting tumor neovascularization and immune checkpoint inhibitors have not yet demonstrated clear clinical benefits. In this review, the most relevant studies and clinical trials on this topic are illustrated and discussed, together with future research directions and challenges.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine and Sciences of Aging, "G. d'Annunzio" University of Chieti-Pescara, 66100 Chieti, Italy.
- Anatomic Pathology and Immuno-Oncology Unit, Center for Advanced Studies and Technology (CAST), "G. d'Annunzio" University of Chieti-Pescara, 66100 Chieti, Italy.
ORCID-Profile: Carlo Sorrentino, Emma Di Carlo
Förderung
- Italian Association for Cancer Research
- Ministero dell'Università e della Ricerca
- AIRC (Associazione Italiana per la Ricerca sul Cancro)
- MUR (Ministero dell’Università e della Ricerca)
- Programma Operativo Nazionale Ricerca e Innovazione 2014–2020 (PON R&I)
Zitieren
APA
Sorrentino, C., & Di Carlo, E. (2023). Molecular Targeted Therapies in Metastatic Prostate Cancer: Recent Advances and Future Challenges. Cancers, 15(11), 2885. https://doi.org/10.3390/cancers15112885
Vancouver
Sorrentino C, Di Carlo E. Molecular Targeted Therapies in Metastatic Prostate Cancer: Recent Advances and Future Challenges. Cancers. 2023;15(11):2885. doi:10.3390/cancers15112885
BibTeX
@article{Sorrentino2023,
author = {Sorrentino, Carlo and Di Carlo, Emma},
title = {Molecular Targeted Therapies in Metastatic Prostate Cancer: Recent Advances and Future Challenges},
journal = {Cancers},
year = {2023},
volume = {15},
number = {11},
pages = {2885},
doi = {10.3390/cancers15112885}
}
EUVIMED